Clinical evaluation of HIFU combined with GnRH-a and LNG-IUS for adenomyosis patients who failed to respond to drug therapies: two-year follow-up results
article
OA: gold
CC0
⤵ 9 in-corpus citations
Abstract
OBJECTIVE: To investigate the clinical effect of high intensity focused ultrasound (HIFU) ablation combined with gonadotropin-releasing hormone agonist (GnRH-a) and levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of adenomyosis patients who failed to respond to drug therapies. STUDY DESIGN: A total of 47 patients with adenomyosis who had failed to respond to drug therapies and had no fertility desires were treated with HIFU combined with GnRH-a and LNG-IUS. The score of dysmenorrhea and menstrual volume were measured at pre and 6-, 12-, 18-, 24-month post-HIFU. RESULTS: > 0.05). The clinical success rate was 100%, 100%, 95.7% and 93.6% respectively at 6, 12, 18 and 24 months after the combined treatment. CONCLUSION: The combined therapeutic regimen of HIFU, GnRH-a and LNS-IUS is safe and effective, which can be an alternative treatment option for patients with adenomyosis who failed to respond to drug therapies to avoid adenomyomectomy or hysterectomy.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (25)
- Clinical Predictors of Long-term Success in Ultrasound-guided High-intensity Focused Ultrasound Ablation Treatment for Adenomyosis via openalex
- Combined therapeutic effects of HIFU, GnRH-a and LNG-IUS for the treatment of severe adenomyosis via openalex
- Comparison of combined transcervical resection of the endometrium and levonorgestrel-containing intrauterine system treatment versus levonorgestrel-containing intrauterine system treatment alone in women with adenomyosis: a prospective clinical trial. via openalex
- Conservative adenomyomectomy with transient occlusion of uterine arteries for diffuse uterine adenomyosis via openalex
- Efficacy of Combined Levonorgestrel-Releasing Intrauterine System with Gonadotropin-Releasing Hormone Analog for the Treatment of Adenomyosis via openalex
- High-intensity focused ultrasound ablation of uterine localized adenomyosis via openalex
- High intensity focused ultrasound for the treatment of adenomyosis: selection criteria, efficacy, safety and fertility via openalex
- High-intensity focused ultrasound (HIFU) combined with gonadotropin-releasing hormone analogs (GnRHa) and levonorgestrel-releasing intrauterine system (LNG-IUS) for adenomyosis: a case series with long-term follow up via openalex
- High intensity focused ultrasound treatment of adenomyosis: a comparative study via openalex
- Long‐term dienogest administration in patients with symptomatic adenomyosis via openalex
- Minimally invasive treatment of adenomyosis via openalex
- Relationship between uterine volume and discontinuation of treatment with levonorgestrel-releasing intrauterine devices in patients with adenomyosis via openalex
- Risk factors of treatment discontinuation due to uterine bleeding in adenomyosis patients treated with dienogest via openalex
- Surgical and medical treatment of adenomyosis via openalex
- The efficacy of the levonorgestrel-releasing intrauterine system in perimenopausal women with menorrhagia or dysmenorrhea via openalex
- The Outcome of Fertility-Sparing and Nonfertility-Sparing Surgery for the Treatment of Adenomyosis. A Systematic Review and Meta-analysis via openalex
- Transvaginal ultrasound for diagnosis of adenomyosis: a review via openalex
- Ultrasound-guided high-intensity focused ultrasound ablation for adenomyosis: the clinical experience of a single center via openalex
- W1606787363 via openalex
- W2042374015 via openalex
- W2160247364 via openalex
- W2033363713 via openalex
- W2736858912 via openalex
- W2790094279 via openalex
- W2805022447 via openalex
Cited by (9)
- Treatment strategies for adenomyosis before and after introducing USgHIFU in Shenzhen 2025
- Risk factors for symptom recurrence after microwave ablation of adenomyosis: a preliminary retrospective study 2024
- Changes of serum CA125 and PGE2 before and after high-intensity focused ultrasound combined with GnRH-a in treatment of patients with adenomyosis 2024
- Individualized conservative therapeutic strategies for adenomyosis with the aim of preserving fertility 2023
- Risk of Recurrence and Reintervention After Uterine-Sparing Interventions for Symptomatic Adenomyosis 2023
- Comparison of the treatment efficacies of HIFU, HIFU combined with GnRH-a, and HIFU combined with GnRH-a and LNG-IUS for adenomyosis: A systematic review and meta-analysis 2023
- Conservative surgical and drug therapies for adenomyosis Medicine 2022
- Anti-Mullerian Hormone (AMH) and adenomyosis: Mini-review of literature of the last 5 years 2022
- Research Progress in Drug Treatment of Adenomyosis 2022
SciLite annotations
chemicals 1
levonorgestrel
Source provenance
- europepmc
- last seen: 2026-06-04T01:30:01.192114+00:00
- openalex
- last seen: 2026-06-04T00:00:01.174412+00:00
- pubmed
- last seen: 2026-05-13T22:24:26.422845+00:00
- scilite
- last seen: 2026-05-18T04:25:29.313245+00:00
License: CC0
· commercial use OK